These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 33264330

  • 1. B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy.
    Cao Z, Meng S, Zheng Y, Wang J, Wang R, Chen X.
    PLoS One; 2020; 15(12):e0242559. PubMed ID: 33264330
    [Abstract] [Full Text] [Related]

  • 2. Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy.
    Cao Z, Meng S, Zheng Y, Wang J, Wang R, Chen X.
    Innate Immun; 2020 Oct; 26(7):601-608. PubMed ID: 32772775
    [Abstract] [Full Text] [Related]

  • 3. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha.
    Cao Z, Liu Y, Ma L, Lu J, Jin Y, Ren S, He Z, Shen C, Chen X.
    Hepatology; 2017 Oct; 66(4):1058-1066. PubMed ID: 28407271
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Low Level of Serum Immunoglobulin G Is Beneficial to Clinical Cure Obtained With Pegylated Interferon Therapy in Inactive Surface Antigen Carriers.
    Li H, Lin X, Liu L, Qin L, Zheng Y, Liu X, Wei X, Liang S, Liu Y, Zhang J, Chen X, Cao Z.
    Front Immunol; 2022 Oct; 13():864354. PubMed ID: 35529845
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.
    Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhashab M, Chuang WL, Tabak F, Mehta R, Petersen J, Guyer W, Jump B, Chan A, Subramanian M, Crans G, Fung S, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HLY.
    Dig Dis Sci; 2018 Dec; 63(12):3487-3497. PubMed ID: 30136045
    [Abstract] [Full Text] [Related]

  • 10. [High rates of HBsAg loss and seroconversion result from prolonged course of pegasys treatment].
    Li MH, Xie Y, Lu Y, Qiu GH, Liu F, Li XH, Zhao H, Song SJ, Guan XP, Cheng J, Xu DZ.
    Zhonghua Gan Zang Bing Za Zhi; 2011 Mar; 19(3):182-5. PubMed ID: 21586235
    [Abstract] [Full Text] [Related]

  • 11. Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort.
    Wiegand J, Brosteanu O, Kullig U, Wiese M, Berr F, Maier M, Tillmann HL, Schiefke I.
    Z Gastroenterol; 2011 Nov; 49(11):1463-9. PubMed ID: 22069045
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.
    Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, Chuang WL, Lim SG, Tabak F, Mehta R, Petersen J, Foster GR, Lou L, Martins EB, Dinh P, Lin L, Corsa A, Charuworn P, Subramanian GM, Reiser H, Reesink HW, Fung S, Strasser SI, Trinh H, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HL, Study 149 Investigators.
    Gastroenterology; 2016 Jan; 150(1):134-144.e10. PubMed ID: 26453773
    [Abstract] [Full Text] [Related]

  • 17. HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study.
    Al Ashgar H, Peedikayil MC, Al Quaiz M, Al Sohaibani F, Al Fadda A, Khan MQ, Thoralsson E, Al Thawadi S, Al Jedai A, Al Kahtani K.
    Saudi J Gastroenterol; 2017 Jan; 23(3):190-198. PubMed ID: 28611343
    [Abstract] [Full Text] [Related]

  • 18. Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy.
    Hsu CW, Yeh CT.
    Hepatology; 2011 Jul; 54(1):101-8. PubMed ID: 21503942
    [Abstract] [Full Text] [Related]

  • 19. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M.
    J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
    [Abstract] [Full Text] [Related]

  • 20. Peginterferon add-on results in more HBsAg decline compared to monotherapy in HBeAg-positive chronic hepatitis B patients.
    Brouwer WP, Sonneveld MJ, Xie Q, Guo S, Zhang N, Zeuzem S, Tabak F, Zhang Q, Simon K, Akarca US, Streinu-Cercel A, Hansen BE, Janssen HL.
    J Viral Hepat; 2016 Jun; 23(6):419-26. PubMed ID: 26403919
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.